Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 8 (2011), Issue 2 (February)

1. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy.
   Int J Radiat Oncol Biol Phys, 79(3): 909-14. [Abstract] [Full-text]
2. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.
   Int J Radiat Oncol Biol Phys, 79(3): 920-6. [Abstract] [Full-text]
3. Vector analysis of prostate patient setup with image-guided radiation therapy via kV cone beam computed tomography.
   Int J Radiat Oncol Biol Phys, 79(3): 915-9. [Abstract] [Full-text]
4. Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer.
   Int J Radiat Oncol Biol Phys, 79(3): 719-23. [Abstract] [Full-text]
5. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.
   Int J Radiat Oncol Biol Phys, 79(3): 724-31. [Abstract] [Full-text]
6. Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns.
   Int J Radiat Oncol Biol Phys, 79(3): 738-46. [Abstract] [Full-text]
7. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.
   Int J Radiat Oncol Biol Phys, 79(3): 713-8. [Abstract] [Full-text]
8. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study.
   Int J Radiat Oncol Biol Phys, 79(3): 732-7. [Abstract] [Full-text]
9. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy.
   Int J Radiat Oncol Biol Phys, 79(3): 909-14. [Abstract] [Full-text]
10. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.
    Int J Radiat Oncol Biol Phys, 79(3): 920-6. [Abstract] [Full-text]
11. Vector analysis of prostate patient setup with image-guided radiation therapy via kV cone beam computed tomography.
    Int J Radiat Oncol Biol Phys, 79(3): 915-9. [Abstract] [Full-text]
12. Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(3): 719-23. [Abstract] [Full-text]
13. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.
    Int J Radiat Oncol Biol Phys, 79(3): 724-31. [Abstract] [Full-text]
14. Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns.
    Int J Radiat Oncol Biol Phys, 79(3): 738-46. [Abstract] [Full-text]
15. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(3): 713-8. [Abstract] [Full-text]
16. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study.
    Int J Radiat Oncol Biol Phys, 79(3): 732-7. [Abstract] [Full-text]
17. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(3): 909-14. [Abstract] [Full-text]
18. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.
    Int J Radiat Oncol Biol Phys, 79(3): 920-6. [Abstract] [Full-text]
19. Vector analysis of prostate patient setup with image-guided radiation therapy via kV cone beam computed tomography.
    Int J Radiat Oncol Biol Phys, 79(3): 915-9. [Abstract] [Full-text]
20. Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(3): 719-23. [Abstract] [Full-text]
21. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose.
    Int J Radiat Oncol Biol Phys, 79(3): 724-31. [Abstract] [Full-text]
22. Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns.
    Int J Radiat Oncol Biol Phys, 79(3): 738-46. [Abstract] [Full-text]
23. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(3): 713-8. [Abstract] [Full-text]
24. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study.
    Int J Radiat Oncol Biol Phys, 79(3): 732-7. [Abstract] [Full-text]
25. Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.
    J Pathol, 223(4): 543-52. [Abstract] [Full-text]
26. Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
    Cancer, 117(4): 752-7. [Abstract] [Full-text]
27. Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.
    J Pathol, 223(4): 543-52. [Abstract] [Full-text]
28. The genomic complexity of primary human prostate cancer.
    Nature, 470(7333): 214-20. [Abstract] [Full-text]
29. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
    Nature, 470(7333): 269-73. [Abstract] [Full-text]
30. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
    Prostate, 71(5): 498-506. [Abstract] [Full-text]
31. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.
    Prostate, 71(5): 550-7. [Abstract] [Full-text]
32. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.
    Prostate, 71(5): 538-49. [Abstract] [Full-text]
33. Urinary estrogen metabolites and prostate cancer risk: a pilot study.
    Prostate, 71(5): 507-16. [Abstract] [Full-text]
34. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Prostate, 71(5): 489-97. [Abstract] [Full-text]
35. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Prostate, 71(5): 470-9. [Abstract] [Full-text]
36. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression.
    Prostate, 71(5): 525-37. [Abstract] [Full-text]
37. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.
    Prostate, 71(5): 480-8. [Abstract] [Full-text]
38. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases.
    Prostate, 71(5): 453-60. [Abstract] [Full-text]
39. A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy.
    Prostate, 71(5): 461-9. [Abstract] [Full-text]
40. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
    Prostate, 71(5): 498-506. [Abstract] [Full-text]
41. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.
    Prostate, 71(5): 550-7. [Abstract] [Full-text]
42. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.
    Prostate, 71(5): 538-49. [Abstract] [Full-text]
43. Urinary estrogen metabolites and prostate cancer risk: a pilot study.
    Prostate, 71(5): 507-16. [Abstract] [Full-text]
44. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Prostate, 71(5): 489-97. [Abstract] [Full-text]
45. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Prostate, 71(5): 470-9. [Abstract] [Full-text]
46. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression.
    Prostate, 71(5): 525-37. [Abstract] [Full-text]
47. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.
    Prostate, 71(5): 480-8. [Abstract] [Full-text]
48. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases.
    Prostate, 71(5): 453-60. [Abstract] [Full-text]
49. A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy.
    Prostate, 71(5): 461-9. [Abstract] [Full-text]
50. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
    Prostate, 71(5): 498-506. [Abstract] [Full-text]
51. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.
    Prostate, 71(5): 550-7. [Abstract] [Full-text]
52. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.
    Prostate, 71(5): 538-49. [Abstract] [Full-text]
53. Urinary estrogen metabolites and prostate cancer risk: a pilot study.
    Prostate, 71(5): 507-16. [Abstract] [Full-text]
54. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Prostate, 71(5): 489-97. [Abstract] [Full-text]
55. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
    Prostate, 71(5): 470-9. [Abstract] [Full-text]
56. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression.
    Prostate, 71(5): 525-37. [Abstract] [Full-text]
57. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists.
    Prostate, 71(5): 480-8. [Abstract] [Full-text]
58. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases.
    Prostate, 71(5): 453-60. [Abstract] [Full-text]
59. A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy.
    Prostate, 71(5): 461-9. [Abstract] [Full-text]
60. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases.
    Am J Surg Pathol, 35(3): 442-6. [Abstract] [Full-text]
61. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.
    Am J Surg Pathol, 35(3): 432-41. [Abstract] [Full-text]
62. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases.
    Am J Surg Pathol, 35(3): 442-6. [Abstract] [Full-text]
63. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.
    Am J Surg Pathol, 35(3): 432-41. [Abstract] [Full-text]
64. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer.
    J Urol, 185(3): 1118-22. [Abstract] [Full-text]
65. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer.
    J Urol, 185(3): 841-7. [Abstract] [Full-text]
66. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
    J Urol, 185(3): 828-32. [Abstract] [Full-text]
67. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
    J Urol, 185(3): 848-54. [Abstract] [Full-text]
68. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.
    J Urol, 185(3): 787-94. [Abstract] [Full-text]
69. Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
    J Urol, 185(3): 869-75. [Abstract] [Full-text]
70. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.
    J Urol, 185(3): 815-20. [Abstract] [Full-text]
71. Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer.
    J Urol, 185(3): 862-8. [Abstract] [Full-text]
72. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden.
    J Urol, 185(3): 833-9. [Abstract] [Full-text]
73. Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis.
    J Urol, 185(3): 821-6. [Abstract] [Full-text]
74. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction.
    Cancer Lett, 302(2): 128-35. [Abstract] [Full-text]
75. Dietary zinc and prostate cancer survival in a Swedish cohort.
    Am J Clin Nutr, 93(3): 586-93. [Abstract] [Full-text]
76. Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy.
    Cancer Sci, 102(3): 639-47. [Abstract] [Full-text]
77. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
    Life Sci, 88(9): 418-24. [Abstract] [Full-text]
78. Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.
    Cancer Immunol Immunother, 60(3): 349-60. [Abstract] [Full-text]
79. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction.
    Cancer Lett, 302(2): 128-35. [Abstract] [Full-text]
80. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    J Cell Physiol, 226(5): 1334-9. [Abstract] [Full-text]
81. Leptin increases motility and integrin up-regulation in human prostate cancer cells.
    J Cell Physiol, 226(5): 1274-82. [Abstract] [Full-text]
82. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway.
    J Cell Physiol, 226(5): 1224-31. [Abstract] [Full-text]
83. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    J Cell Physiol, 226(5): 1334-9. [Abstract] [Full-text]
84. Leptin increases motility and integrin up-regulation in human prostate cancer cells.
    J Cell Physiol, 226(5): 1274-82. [Abstract] [Full-text]
85. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway.
    J Cell Physiol, 226(5): 1224-31. [Abstract] [Full-text]
86. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    J Cell Physiol, 226(5): 1334-9. [Abstract] [Full-text]
87. Leptin increases motility and integrin up-regulation in human prostate cancer cells.
    J Cell Physiol, 226(5): 1274-82. [Abstract] [Full-text]
88. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway.
    J Cell Physiol, 226(5): 1224-31. [Abstract] [Full-text]
89. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
    Int J Cancer, 128(8): 1946-54. [Abstract] [Full-text]
90. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
    Int J Cancer, 128(8): 1946-54. [Abstract] [Full-text]
91. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
    J Nucl Med, 52(3): 470-7. [Abstract] [Full-text]
92. Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure.
    Int J Radiat Oncol Biol Phys, 79(4): 1029-36. [Abstract] [Full-text]
93. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(4): 1022-8. [Abstract] [Full-text]
94. Treatment results of PDR brachytherapy combined with external beam radiotherapy in 106 patients with intermediate- to high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(4): 1037-42. [Abstract] [Full-text]
95. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(4): 1013-21. [Abstract] [Full-text]
96. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial).
    Int J Radiat Oncol Biol Phys, 79(4): 1004-12. [Abstract] [Full-text]
97. Proteasome inhibitor-I enhances tunicamycin-induced chemosensitization of prostate cancer cells through regulation of NF-κB and CHOP expression.
    Cell Signal, 23(5): 857-65. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.